Eastern Cooperative Oncology Group
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2012-01-01
- Employees
- 51
- Market Cap
- -
- Website
- https://ecog-acrin.org
Clinical Trials
177
Active:3
Completed:147
Trial Phases
4 Phases
Phase 1:4
Phase 2:96
Phase 3:40
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (152 trials with phase data)• Click on a phase to view related trials
Phase 2
96 (63.2%)Phase 3
40 (26.3%)Not Applicable
12 (7.9%)Phase 1
4 (2.6%)A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients
Not Applicable
Not yet recruiting
- Conditions
- Cutaneous Melanoma
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 428
- Registration Number
- NCT07068074
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Patients With a Prior History of Melanoma
Not Applicable
Not yet recruiting
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 120
- Registration Number
- NCT07040280
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Extended Clinical Follow up and Biospecimen Collection for Patients Enrolled in TAILORx and RxPONDER: A Companion Protocol
Not yet recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 600
- Registration Number
- NCT06786585
The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials
Not Applicable
Recruiting
- Conditions
- Cancer
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 500
- Registration Number
- NCT06756607
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Phase 3
Not yet recruiting
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-NegativeFollicular Helper T-Cell LymphomaFollicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypePeripheral T-Cell Lymphoma, Not Otherwise Specified
- Interventions
- Other: Best PracticeProcedure: Autologous Hematopoietic Stem Cell TransplantationProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Positron Emission TomographyDrug: High Dose ChemotherapyProcedure: LeukapheresisDrug: Stem Cell Mobilization Therapy
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 294
- Registration Number
- NCT06724237
- Prev
- 1
- 2
- 3
- 4
- 5
- 36
- Next
News
No news found